Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes
2016 ASCO Annual Meeting
Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). To see the French language version of this discussion, click here.
Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether physician-assisted death should be a legally available option at the end of life when neither palliative nor hospice care is satisfactory.
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Caroline Robert, MD, PhD, of Gustave Roussy and Paris-Sud University, discuss study findings on pembrolizumab and the overall survival benefit for patients with advanced disease (Abstract 9503).
Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.
Lisa A. Carey, MD, of the University of North Carolina, and Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital and Institute of Cancer Research, discuss the efficacy of palbociclib plus fulvestrant in patients with ESR1 mutations in circulating tumor DNA, and palbociclib and letrozole for postmenopausal women with ER+/HER2–advanced breast cancer (Abstracts 507, 524).
The
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, and Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discuss findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).
